日本《日经亚洲评论》6月29日文章，原题：随着中美贸易摩擦继续，美国花旗参种植者濒临崩溃 根据 威斯康星州农业、贸易和消费者保护部的数据，威斯康星州是美国最大的花旗参产地，占该国人参总产 量的98%，而中国是其最大买家之一。 海外买家通常在年初开始采购，但由于中美贸易摩擦，4月后销往中国的货物运输陷入停滞。波动的关 税政策和限制措施已使全球贸易陷入深度不确定性。威斯康星州马拉松县的花旗参种植户承受着贸易战 的巨大冲击，因为价格持续低迷，去年收获的作物仍堆积在仓库中。种植者表示，去年收成剩余的根茎 数量异常多，因为大多数买家推迟采购以等待关税政策最终落地。"当你不知道市场会是什么样子时， 该如何种植？"参农威尔感叹道，并表示他计划缩小下一季花旗参种植面积。 中国内地和香港一直是美国花旗参的前两大出口市场。去年，美国向两地共出口了价值3250万美元的花 旗参，占该产品全球出口总额的83%。 农产品是美国对华出口的最大类商品之一。自特朗普政府首次执政期间爆发贸易争端以来，美国农产品 在中国市场的份额持续下降，许多农民担心此次的贸易争端会导致他们破产。 花旗参至少需要3年到4年才能成熟收割，许多种植者因商品价格低迷和 ...

Core Points - The article reports on the disciplinary actions taken against several officials for violations related to accepting gifts and hosting banquets that could influence their official duties [1][2][3][4][5] Summary by Relevant Sections Violations and Disciplinary Actions - Lin Youzhi, former deputy director of Sanya Municipal People's Congress, received gifts including Moutai liquor and Huawei phones from 2016 to 2019, and was expelled from the party and public office in December 2024 [1] - Wu Qifang, a second-level researcher at the Provincial Forestry Bureau, accepted gifts such as Moutai liquor and Chinese cigarettes in 2024, receiving a serious warning in April 2025 [1] - Long Shuhua, former first-level researcher at Haikou Natural Resources and Planning Bureau, received supermarket shopping cards and Moutai liquor from 2013 to 2022, expelled from the party in November 2024 [2] - Zhou Zhijian, former member of the Party Leadership Group of Chengmai County Science and Technology Association, accepted banquets and gifts from 2020 to 2021, expelled from the party in January 2025 [3] - Guo Xing, former manager of Qionghai Water Company, received gifts including cordyceps and ginseng from 2019 to 2021, expelled from the party in February 2025 [4] - Wang Fuhai, former head of the Environmental Sanitation Management Station in Lingao County, received gifts and hosted banquets from 2016 to 2020, expelled from the party in November 2024 [4]

继羽衣甘蓝后，喜茶、奈雪、M stand、挪瓦咖啡等咖饮品牌们又迷上将红菜头、巴西莓、姜黄等冷门的"超级植物"加入 到菜单中。 植物咖饮，品牌推新的流量密码 近期，"超级植物"在咖饮圈爆火。 "超级植物"一词源自西方概念"超级食物"的延伸，通常代指营养密度高，富含维生素的健康植物的统称。《现制饮品新 品趋势观察报告2024》显示，超级植物是2024年新茶饮的"黑马选手"，喜茶、奈雪的茶、茶百道、茶救星球等多个茶饮 品牌，均推出了羽衣甘蓝、红菜头、奇异果等，主打纤体、减脂、养颜功效的超级植物果蔬茶。 △图片来源：图虫创意 来到2025年，在刚结束不久的2025 HOTELE上海展上，红餐网也留意到，除了"顶流"羽衣甘蓝，各种"超级植物"频繁出 现在各大茶咖品牌的展位中，其中巴西莓、红菜头和姜黄的热度颇高，大有成为"超级植物"新顶流的趋势。 譬如最近风头正盛的红菜头（甜菜根），因富含膳食纤维和维生素C，就被不少咖饮品牌纳入新产品中。 …… 4月中旬喜茶推出新品"木姜子滇木瓜"，将木姜子和酸木瓜融入到饮品内，内含手工刨制成全新小料"木姜子豌豆凉粉"， 备受消费者关注；古茗则推出"大橘姜黄"新品，率先把姜黄应用在奶茶 ...

Core Insights - Health元 reported a total revenue of 15.619 billion yuan and a net profit attributable to shareholders of 1.387 billion yuan for the year 2024, with a net operating cash flow of 3.636 billion yuan [1] - The company has established a strong position in the respiratory drug market, achieving a 22-fold growth in respiratory products since the launch of its first high-end inhalation formulation in 2019 [1][2] - Health元 is advancing its innovative drug pipeline in the respiratory field, with over 10 innovative drugs in development, including the flu drug "Marpacisavir," which has completed Phase III clinical trials [2][3] Revenue and Profitability - The company achieved an operating revenue of 15.619 billion yuan and a net profit of 1.387 billion yuan for 2024 [1] - The net profit after deducting non-recurring items was 1.319 billion yuan, indicating a strong financial performance [1] Product Development and Innovation - Health元 has developed over 10 first-class innovative drugs in the respiratory field, covering inhalation, oral, and injection forms [2] - The flu drug "Marpacisavir" has shown superior treatment effects, significantly shortening the duration of flu symptoms and demonstrating rapid relief for adolescents [2] - The company is also focusing on chronic obstructive pulmonary disease (COPD) with multiple first-in-class drugs, including TSLP monoclonal antibody and IL-4R monoclonal antibody, both in Phase II clinical trials [2] Strategic Collaborations - Health元 is collaborating with Bayer to develop a novel oral drug for COPD, which is a global first in its class, targeting the PREP enzyme to control inflammation [3] Embracing AI Technology - The company has begun integrating AI technology across its business operations to enhance efficiency and accelerate drug development processes [5] - Health元 has deployed advanced AI models for target identification, molecular design, and screening, significantly reducing research and development timelines [5] Future Outlook - The global pharmaceutical industry is undergoing significant transformation, with AI technology reshaping drug development paradigms [6] - Health元 aims to position itself as a leader in innovative respiratory drugs in the Chinese A-share market [3][6]